Using AI to predict diabetic neurodegenerative disorders through retinal imaging

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the risk of diabetic neurodegenerative disorders by utilizing artificial intelligence tools that analyze retinal imaging. It focuses on patients with type 2 diabetes and examines the relationship between retinal vascular abnormalities and cognitive impairment. By employing deep-learning convolutional neural networks, the study seeks to identify clinical metrics and systemic conditions that may not be visible to human observers. The goal is to establish a non-invasive method for predicting complications associated with diabetes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female \> 45 years-old;
2. Diagnosis of type 2 DM;
3. No previous treatment for diabetic retinopathy;
4. Clear ocular media;
5. Ability to communicate well with the Investigator and to understand and comply with the requirements of the study;
6. Ability to provide written informed consent in accordance with institutional, local and national regulatory guidelines and to attend all study visits

Exclusion Criteria:

1. Patients affected by other retinal disease than diabetic retinopathy;
2. Presence of diabetic macular edema;
3. Presence of proliferative diabetic retinopathy;
4. Any media opacities, including corneal opacity, cataract formation and hemorrhage in the vitreous body, which may interfere with viewing by the laser surgeon of the target structures in the study eye(s). Subject requiring cataract surgery in the next 12 months must be excluded;
5. Aphakic eye(s) with vitreous in the anterior chamber;
6. Neovascular glaucoma;
7. Glaucoma caused by congenital angle anomalies;
8. Open angle of less than 90º or extensive peripheral anterior and low synechia, present circumferentially around the corner;
9. Glaucoma secondary to active uveitis;
10. Any other ocular condition that would progress in the study period and confound visual acuity assessment a part from diabetic retinopathy;
11. Presence of idiopathic or autoimmune-associated uveitis;
12. Any ocular or systemic medication known to be toxic to the lens, retina or optic nerve;
13. Any intra-ocular surgery on a qualifying eye within three months prior to entry in the study;
14. Any prior thermal laser in the macula or intravitreal injections or panphotocoagulation;
15. History of vitrectomy, filtering surgery, corneal transplant or retinal detachment surgery;
16. Previous therapeutic radiation in the ocular region in either eye;
17. Participation in an investigational drug, biologic, or device study within 6 months prior to baseline \[Note: observational clinical studies solely involving over-the-counter vitamins, supplements, or diets are not exclusionary\];
18. Has a serious medical illness that will prevent the subject from performing study activities (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease) or, in the judgement of the Investigator, is likely to require surgical intervention or hospitalization at any point during the study;
19. In the opinion of the Investigator, is unlikely to comply with the study protocol.

Where it's running

• Ospedale San Raffaele
  Milan, Italy Recruiting

Study contacts

• Study coordinator: Giuseppe Querques, MD, PhD
• Email: giuseppe.querques@hotmail.com
• Phone: 00390226432648

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Differentiating heart disease in autoimmune vs. type 2 diabetes

  This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.

  Recruiting University of Roma La Sapienza · Rome, Roma · NCT07911007

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• Reset-INSPIRE: See if CGM can reveal insulin sensitivity in people at risk for MASLD

  This study tests whether real-time CGM data can accurately reflect insulin sensitivity in adults without diabetes who are at risk for MASLD.

  Recruiting National University Health System, Singapore · Singapore, Singapore · NCT07861191

• Biomarkers That Signal Silent Strokes in High-Risk Cardiac Procedures

  This study tests whether blood biomarkers NSE and NFLs can predict silent brain injuries and later cognitive problems in adults having high-risk transcatheter heart procedures.

  Recruiting Aristotle University Of Thessaloniki · Thessaloniki · NCT07844850

• Blood-based tests and digital cognitive checks to help triage dementia

  This study tests whether adding blood biomarkers, APOE4 genetic info, and digital cognitive tests can help dementia diagnosis be faster in NHS Memory Clinics.

  Recruiting at 11 sites Prima Mente · London, Greater London and 11 other locations · NCT07842029

• Cardiovascular and Cognitive Health Initiative

  This study tests whether targeted cognitive and heart-health interventions can help improve thinking skills in adults with cardiovascular disease.

  Recruiting National Heart Centre Singapore · Singapore and 3 other locations · NCT07829380

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.